See What HealthDay Can Do For You
Contact Us

Clinical Trials Update: Oct.14, 2002

Depression (Treatment-Resistant) Diabetes Type II Urinary Incontinence

(HealthDayNews) --

Here are the latest clinical trials, courtesy of CenterWatch.

Depression (Treatment-Resistant)

The research study of Olanzapine Plus Fluoxetine in Combination for Treatment-Resistant Depression without psychotic features. The purposes of this study are to determine whether olanzapine plus fluoxetine will help patients with treatment-resistant major depression, the safety of olanzapine plus fluoxetine and any side effects that might be associated with the combination and the effectiveness of olanzapine plus fluoxetine compared to olanzapine and fluoxetine alone. Research sites throughout the world.

More Information

Please see http://www.centerwatch.com/patient/studies/cat46.html.

-----

Diabetes Type II

The purpose of this research study is to test several different dose strengths of GW427353B in volunteers with type II diabetes (sometimes called adult onset diabetes or non insulin dependent diabetes) to see if it is safe and well tolerated when given once or twice a day for 12 days. Research site in Seattle, WA.

More Information

Please see http://www.centerwatch.com/patient/studies/cat55.html.

-----

Urinary Incontinence

A short term, four visit, phase II clinical research study to evaluate the dose response characteristics of an approved medication in patients with a diagnosis of Overactive Bladder or Urge Incontinence. Research site located in Sandy, UT.

More Information

Please see http://www.centerwatch.com/patient/studies/cat195.html.

-----

Copyright 2002 Centerwatch. All rights reserved.

Consumer News

HealthDay

HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.